Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathwayby a somatostatin analogue

Clinical Cancer Research

Volumn 15, Issue 8, 2009, Pages 2620-2629

  Horiguchi, Kazuhiko ^a   Yamada, Masanobu ^a   Satoh, Tetsurou ^a   Hashimoto, Koshi ^a   Hirato, Junko ^a   Tosaka, Masahiko ^a   Yamada, Shozo ^b   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

10.1158 1078 0432

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; METHIONINE; METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE LEUKEMIA PROTEIN; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; BASE SEQUENCE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P18; ENDOCRINE GLAND NEOPLASMS; FEMALE; FLAVONOIDS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR SEQUENCE DATA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; OCTREOTIDE; PITUITARY NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 65249091422     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2473     Document Type: Article

References (39)

1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613-9.
2. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 2001;8:287-305.
3. Ferjoux G, Bousquet C, Cordelier P, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 2000;94: 205-10.
4. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334: 246 -54.
5. Hubina E, NanzerAM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006;155:371 -9.
6. Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006;66:1576 -82.
7. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707 -20.
8. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin- dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721 -32.
9. Fero ML, Rivkin M,Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tu- morigenesis, and female sterility in p27(Kip1)-defi- cient mice. Cell 1996;85:733-44.
10. Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitarytumori- genesis. Genes Dev1998;12:2899 -911.
11. Suhardja AS, Kovacs KT, RutkaJT. Molecularpatho- genesis of pituitary adenomas: a review. Acta Neuro- chir (Wien) 1999;141:729 -36.
12. Cristina C, Garcia-Tornadu I, Diaz-Torga G, Rubinstein M, Low MJ, Becu-Villalobos D. Dopami- nergic D2 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res 2006;35:50-63.
13. Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 1991;88: 10735-9.
14. Yokoyama A, Wang Z, Wysocka J, et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 2004;24: 5639 -49.
15. Milne TA, Briggs SD,Brock HW,et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002;10:1107 -17.
16. Hughes CM, Rozenblatt-Rosen O, MilneTA, et al. Menin associates with a trithorax familyhistonemeth- yltransferase complex and with the hoxc8 locus. Mol Cell 2004;13:587 -97.
17. MilneTA, Hughes CM, Lloyd R, et al. Menin and MLL cooperatively regulate expression of cyclin- dependent kinase inhibitors. Proc Natl Acad Sci USA2005;102:749-54.
18. Karnik SK, Hughes CM, Gu X, et al. Menin regulates pancreaticislet growth by promoting histonemethyla- tion and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A 2005;102: 14659 - 64.
19. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A2006;103:15558-63.
20. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276: 404-7.
21. Vierimaa O,Georgitsi M, Lehtonen R,et al.Pituitary adenoma predisposition caused by germline mutations in theAIP gene. Science 2006;312:1228-30.
22. Yamada M, SagaY, Shibusawa N, et al. Tertiary hy- pothyroidism and hyperglycemia in micewith targeted disruption of the thyrotropin-releasing hormone gene. Proc Natl Acad Sci U S A1997;94:10862 -7.
23. Shibusawa N, Yamada M, Hirato J, Monden T, Satoh T, Mori M. Requirement of thyrotropin-releasing hormone for thepostnatal functions ofpituitarythyro- trophs: ontogeny study of congenital tertiary hypo- thyroidism in mice. Mol Endocrinol 2000;14:137 -46.
24. Lidhar K, Korbonits M, Jordan S, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corti- cotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999;84: 3823-30.
25. Dahia PL, Aguiar RC, Honegger J, et al. Mutation and expression analysis of the p27/kip1 gene in cor- ticotrophin-secreting tumours. Oncogene 1998;16: 69-76.
26. Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphorylated p27(Kip1) protein andJun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002;87:2635 -43.
27. Musat M, Korbonits M, Pyle M, et al. The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors. Pituitary 2002;5:235 -42.
28. Karnik SK, Chen H, McLean GW, et al. Menincontrols growth of pancreatic h-cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007;318:806-9.
29. Monni O,Knuutila S. 11q deletions in hematological malignancies. Leuk Lymphoma 2001;40:259 -66.
30. Guo C,White PS,Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene1999;18:4948-57.
31. Herbst RA, Gutzmer R, Matiaske F, et al. Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma. Int J Cancer 1999;80: 205 -9.
32. Caslini C,Shilatifard A, Yang L,Hess JL.Theamino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation. Proc Natl Acad Sci U S A 2000;97:2797 -802.
33. Caslini C,Alarcon AS, Hess JL,Tanaka R,Murti KG, Biondi A. The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds. Leukemia 2000;14:1898-908.
34. Susini C, Buscail L. Rationalefor theuseofsomato- statin analogs as antitumor agents. Ann Oncol 2006; 17:1733-42.
35. Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everoli- mus) block proliferation and interact with the Akt- mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008;87:168-81.
36. 1 cell cycle block. Endocrinology1995;136:4174-81.
37. Hubina E, Ruscica M, NanzerAM, et al. Novel molecular aspects ofpituitaryadenomas. J Endocrinol Invest 2005;28:87 -92.
38. Ewing I, Pedder-Smith S, Franchi G, et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 2007;66: 348-52.
39. Mensah-Osman E, ZavrosY, MerchantJL. Somato- statin stimulates menin gene expression by inhibiting protein kinase A. Am J Physiol Gastrointest Liver Physiol 2008;295:G843 -54.